Home
Insights
Team
Contact
Login
Insights: Healthcare
Clients
Healthcare
Medicare Extenders
An offset to the -2.8% cut to Medicare Physician Fee Schedule (PFS) payments for CY25 was not included in the House-passed continuing resolution (CR), which would fund the government for the remainder of FY25 (through September)). Rep. Murphy (R-NC) – a member of the GOP Doctors Caucus and a leader on this issue – has indicated that House...
Clients
Healthcare
Affordable Care Act (ACA) Exchanges
HHS has issued a proposed rule entitled “ACA Individual Health Insurance Market & Exchange Program Integrity,” which includes regulatory changes that would limit access to ACA individual market plans and eligibility for premium subsidies. As constructed, HHS projects the rule would decrease enrollment by 750k to 2.1m (total) between 2026 and 2029...
Clients
Healthcare
Nutrition Policy
HHS Secretary Kennedy has directed the FDA to consider rulemaking to eliminate the self-affirmed “Generally Recognized as Safe” (GRAS) pathway, which currently allows companies to determine the safety of food ingredients without notifying the agency or the public.
Clients
Healthcare
HHS Rulemaking Process
Late last week, the Department of Health & Human Services (HHS) rescinded a 1970’s memo, referred to as the “Richardson Waiver,” under which the agency agreed to (1) follow the notice-and-comment rulemaking process for rules related to “agency management or personnel or to public property, loans, grants, benefits, or contracts” and (2) sparingly...
Clients
Healthcare
Medicare Extenders
Republican Congressional and committee leaders are working to develop a “continuing resolution” (CR) to extend FY25 funding/appropriations beyond the current 3/14 deadline. Lawmakers are jockeying to have their preferred “riders” (provisions extraneous to ordinary annual government funding) added to that measure and in recent days, Rep. Murphy...
Clients
Healthcare
GLP-1s
Late last week, the FDA issued a Declaratory Order determining that the semaglutide drug shortage has been resolved and announcing that the drug (the active ingredient in Ozempic, Rybelsus, and Wegovy) would be removed from the agency’s 506e shortage list. Just days later, the Outsourcing Facilities Association (OFA) – which represents the...
Pages:
Previous
1
2
3
4
5
6
7
8
Next
↑